Article
Decreased Infliximab Concentrations in Patients With Inflammatory Bowel Disease Who Carry a Variable Number Tandem Repeat Polymorphism in the Neonatal Fc Receptor or Variant HLADQA1*05G>A Genotype.
Inflammatory bowel diseases - 1 Mar 2023
Choi Bethany, Sey Michael, Ponich Terry, Beaton Melanie, Kim Richard, Wilson Aze
Abstract excerpt
BACKGROUND: Multiple variables contribute to variation in patient exposure and response to tumor necrosis factor alpha antagonist biologics such as infliximab. This study aimed to assess the association between maintenance-phase infliximab concentrations and genetic variation in HLADQA1*05G>A and fragment crystallisable (Fc) fragment of IgG receptor and transporter (FCGRT) among patients with inflammatory bowel...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.